Edoxaban regulatory update

Daiichi Sankyo submitted an MAA to EMA and NDA to FDA for edoxaban, an oral Factor Xa inhibitor. The pharma is seeking approval of the product in the EU and U.S. to prevent stroke and systemic emboli...